RICHMOND, Va., Nov. 30, 2011 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. (HDL, Inc.) announced today that medical advisory board member Michael F. Richman M.D., F.A.C.S., founder of the Center for Cholesterol Management and The Elite Laser Vein Center in Los Angeles, has initiated a study that will analyze the relevance of MTHFR polymorphisms in venous disease with or without concomitant thrombosis.
It has been reported that a mutation in the gene encoding methylenetetrahydrofolate reductase (MTHFR) is associated with both varicose veins (Svedlova et al., 1998) and superficial venous thrombosis (Wilmanns et al., 2011). "The etiologies of varicose veins and the progression to more serious forms of chronic venous disease are still not well understood, and identification of appropriate diagnostic tests to better stratify risk could aid patient management by identifying individuals who may benefit from more aggressive treatment and/or prophylactic measures," said Dr. Michael Richman.
This is a cross-sectional, observational study comparing MTHFR status as well as several other genetic and acquired thrombophilic factors in patients with varicose veins vs. controls, with low (C2-C3) vs. high (C4-C6) severity venous disease, and with vs. without associated venous thrombosis. A total of 90 subjects will be enrolled; 60 subjects with varicose veins (30 C2-C3 and 30 C4-C6) and 30 controls with no evidence of venous disease. Baseline and 3 month follow-up visits will include relevant clinical assessments (including determination of thromboses by duplex sonography, medical and family history, and blood draws for laboratory testing).
"The prevalence of each mutation will be compared between study groups with Pearson's Chi-Square test, and odds ratios with 95% confidence intervals will be calculated," said Dr. Richman. Analysis of Variance (ANOVA) will be used to compare laboratory values between the study groups. <